Takeda is promoting U.S. chief Julie Kim to be its next CEO. AstraZeneca and Daiichi's Enhertu has won an FDA nod to expand into HER2-ultralow breast cancer. | Takeda is promoting U.S. chief Julie Kim ...

Vertex has gained the FDA's approval for its non-addictive pain med Journavx, which becomes the first significant innovation ...

After playing ball Wednesday during his first confirmation hearing with the Senate Finance Committee, Robert F. | Sens. Bill ...

While Sanofi’s immunology megablockbuster Dupixent predictably dominated the company’s sales charts in 2024, a new golden ...

After repeatedly wowing investors, Roche’s star eye med Vabysmo collected more than $4 billion in sales during its third year ...

U.K.-based CDMO Upperton Pharma Solutions expanded its production footprint with the completion of a new £7 million ($8.1 ...

CDMO Rentschler Biopharma is moving out of the cell and gene therapy space and putting more of its chips behind biologics. | The German manufacturer is ending operations at its Stevenage, U.K., site ...

Takeda has named Julie Kim as its next CEO. She will replace Christophe Weber who plans to step down in June of 2026 after leading Japan’s largest drugmaker for 11 years. | Takeda has named Julie Kim ...

Although Lonza posted slightly lower sales than analysts had expected in 2024, the Swiss CDMO suggested in its year-end ...

All patients in the trial will have the opportunity to resume or begin treatment with Winrevair, the company said.

President Donald Trump’s nominee for secretary of the Department of Health and Human Services (HHS), Robert F. Kennedy Jr. | ...

Despite finishing strong across both its innovative and generic businesses in 2024, Teva’s cautious approach to the new year ...